Search Results

The Advantage hCG Test (Urine/Serum) is a qualitative, rapid immunochromatographic assay used to detect the presence of hCG in human urine and serum for the early detection of pregnancy. The test is intended for use in clinical laboratories by health care professionals.

The Advantage hCG Test (Urine/Serum) is an immunochromatographic based one step in vitro test.

The Advantage Diagnostics Corporation Advantage hCG Test (Urine/Serum) is an immunochromatographic assay designed for the qualitative detection of hCG in human urine and serum as an early indication of pregnancy.

Here's an analysis of its acceptance criteria and the study proving its performance:

Acceptance Criteria and Reported Device Performance

Study Details

1. Sample size used for the test set and the data provenance:

   • Serum samples: 100 samples (51 positive and 49 negative)
   • Urine samples: 105 samples (40 positive and 65 negative)
   • Data Provenance: The document does not explicitly state the country of origin. It is implied to be clinical samples from pregnant and non-pregnant women. The study appears to be retrospective, as it describes the evaluation of existing samples.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • The document does not specify the number of experts or their qualifications for establishing ground truth. The ground truth appears to be based on the established pregnancy status of the women from whom the samples were collected.

3. Adjudication method for the test set:

   • The document does not describe an adjudication method. It states that the samples were evaluated and compared, implying a direct comparison of results between the test device and the predicate device, against known pregnancy status.

4. If a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was done:

   • No, an MRMC comparative effectiveness study was not done. This study focuses on the analytical performance of the device in detecting hCG and its correlation with a predicate device, rather than the impact of the device on human reader performance.

5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

   • Yes, a standalone study was done. The Advantage hCG Test is an in-vitro diagnostic device (immunochromatographic assay), meaning its performance is evaluated based on its ability to detect the analyte (hCG) in samples, independent of human interpretation beyond reading the test result itself. The study compared the device's results directly with a predicate device and the known status of the samples.

6. The type of ground truth used:

   • The ground truth was based on the known pregnancy status of the women from whom the urine and serum samples were collected (i.e., "pregnant and non pregnant women"), along with the results from the predicate device. While not explicitly stated as "clinical outcomes data," the known pregnancy status serves as the ultimate clinical ground truth for hCG detection.

7. The sample size for the training set:

   • The document does not mention a training set as this is an in-vitro diagnostic device (immunochromatographic assay) and likely does not involve machine learning algorithms that require separate training and test sets in the traditional sense. The study described is a performance evaluation or validation study.

8. How the ground truth for the training set was established:

   • As no training set is mentioned or applicable in the context of this device technology, the method for establishing its ground truth is not applicable.

Ask a specific question about this device